National Center for Complementary & Alternative Medicine; Notice of Meeting, 76019-76020 [2010-30641]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 234 / Tuesday, December 7, 2010 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0550]
Compliance Policy Guide Sec. 390.500
Definition of ‘‘High-Voltage Vacuum
Switch’’—21 CFR 1002.61(a)(3) and
(b)(2); Withdrawal of Guidance
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; withdrawal.
The Food and Drug
Administration (FDA) is announcing the
withdrawal of Compliance Policy Guide
Sec. 390.500 Definition of ‘‘High-Voltage
Vacuum Switch’’—21 CFR 1002.61(a)(3)
and (b)(2) (CPG Sec. 390.500). CPG Sec.
390.500 is included in FDA’s
Compliance Policy Guides Manual,
which was listed in the Annual
Comprehensive List of Guidance
Documents that published on August 9,
2010.
DATES: The withdrawal is effective
December 7, 2010.
FOR FURTHER INFORMATION CONTACT:
Sean M. Boyd, Center for Devices and
Radiological Health, Office of
Communication, Education, and
Radiological Programs, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 4640, Silver Spring,
MD 20993–0002, 301–796–5895.
SUPPLEMENTARY INFORMATION: In a notice
containing a cumulative list of
guidances available from the agency that
published in the Federal Register of
August 9, 2010 (75 FR 48180 at 48233),
FDA included the Compliance Policy
Guides Manual, which includes CPG
Sec. 390.500. FDA is withdrawing CPG
Sec. 390.500 because it is obsolete.
SUMMARY:
Dated: November 22, 2010.
Dara Corrigan,
Associate Commissioner for Regulatory
Affairs.
[FR Doc. 2010–30677 Filed 12–6–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
emcdonald on DSK2BSOYB1PROD with NOTICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council for
Biomedical Imaging and Bioengineering.
VerDate Mar<15>2010
18:39 Dec 06, 2010
Jkt 223001
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering NACBIB January 2011.
Date: January 24, 2011.
Open: 8:30 a.m. to 1 p.m.
Agenda: Report from the Institute Director,
other Institute Staff and discussion of
strategic plan.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Independence Room
(2nd Level), Bethesda, MD 20817.
Closed: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Independence Room
(2nd Level), Bethesda, MD 20817.
Contact Person: Anthony Demsey, PhD,
Director, National Institute of Biomedical
Imaging and Bioengineering, 6707
Democracy Boulevard, Room 241, Bethesda,
MD 20892.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib1.nih.gov/about/NACBIB/
NACBIB.htm, where an agenda and any
additional information for the meeting will
be posted when available.
Dated: December 1, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–30644 Filed 12–6–10; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
76019
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Alternative Medicine; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the National Advisory
Council for Complementary and
Alternative Medicine (NACCAM)
meeting.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The grant applications
and/or contract Proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable materials, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Complementary and Alternative
Medicine.
Date: February 4, 2011.
Closed: February 4, 2011, 8:30 a.m. to
10:30 a.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Open: February 4, 2011, 11 a.m. to 4 p.m.
Agenda: Opening remarks by the Director
of the National Center for Complementary
and Alternative Medicine, presentation of a
new research initiative, and other business of
the Council.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Martin H. Goldrosen, PhD,
Executive Secretary, Director, Division of
Extramural Activities, National Center for
Complementary and Alternative Medicine,
National Institutes of Health, 6707
Democracy Blvd., Suite 401, Bethesda, MD
20892. (301) 594–2014.
The public comments session is scheduled
from 3:30 to 4 p.m. on February 4, 2011, but
could change depending on the actual time
spent on each agenda item. Each speaker will
be permitted 5 minutes for their presentation.
Interested individuals and representatives of
E:\FR\FM\07DEN1.SGM
07DEN1
76020
Federal Register / Vol. 75, No. 234 / Tuesday, December 7, 2010 / Notices
organizations are requested to notify Dr.
Martin H. Goldrosen, National Center for
Complementary and Alternative Medicine,
NIH, 6707 Democracy Boulevard, Suite 401,
Bethesda, Maryland 20892, 301–594–2014,
Fax: 301–480–9970. Letters of intent to
present comments, along with a brief
description of the organization represented,
should be received no later than 5 p.m. on
January 26, 2011. Only one representative of
an organization may present oral comments.
Any person attending the meeting who does
not request an opportunity to speak in
advance of the meeting may be considered
for oral presentation, if time permits, and at
the discretion of the Chairperson. In
addition, written comments may be
submitted to Dr. Martin H. Goldrosen at the
address listed above up to ten calendar days
(February 14, 2011) following the meeting.
Copies of the meeting agenda and the
roster of members will be furnished upon
request by contacting Dr. Martin H.
Goldrosen, Executive Secretary, NACCAM,
National Center for Complementary and
Alternative Medicine, National Institutes of
Health, 6707 Democracy Boulevard, Suite
401, Bethesda, Maryland 20892, 301–594–
2014, Fax 301–480–9970, or via e-mail at
naccames@mail.nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
nccam.nih.gov/about/naccam, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.701, ARRA Related
Biomedical Research and Research Support
Awards; 93.213, Research and Training in
Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: November 30, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Devices for Treating
Dysphagia and Dysphonia
National Institutes of Health,
Public Health Service, HHS
AGENCY:
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
worldwide license to practice the
invention embodied in: HHS Ref. No. E–
251–2005/0,/1,/2:
SUMMARY:
[FR Doc. 2010–30641 Filed 12–6–10; 8:45 am]
BILLING CODE 4140–01–P
Patent/application number
Territory
Filing date
60/695,424 ......................................................................
60/787,215 ......................................................................
PCT/US2006/025535 ......................................................
PCT/US2007/007993 ......................................................
PCT/US2009/57158 ........................................................
2006265985 ....................................................................
2,614,072 ........................................................................
06785933.0 .....................................................................
2008–520302 ..................................................................
11/993,094 ......................................................................
08112281.5 .....................................................................
12/240,398 ......................................................................
12/211,633 ......................................................................
US ....................
US ....................
Intl ....................
Intl ....................
Intl ....................
AU ....................
CA ....................
EP ....................
JP .....................
US ....................
HK ....................
US ....................
US ....................
July 1, 2005 ...................................................................
March 30, 2006 ..............................................................
June 30, 2006 ................................................................
March 20, 2007 ..............................................................
September 16, 2009 ......................................................
December 18, 2007 .......................................................
June 30, 2006 ................................................................
June 30, 2006 ................................................................
June 30, 2006 ................................................................
December 19, 2007 .......................................................
November 5, 2008 .........................................................
September 29, 2008 ......................................................
September 16, 2008 ......................................................
to Passy-Muir, Inc., a company
incorporated under the laws of the State
of California having its headquarters in
Irvine, California. The United States of
America is the assignee of the rights of
the above inventions. The contemplated
exclusive license may be granted in a
field of use limited to devices for
treating dysphagia and dysphonia.
Only written comments and/or
applications for a license received by
the NIH Office of Technology Transfer
on or before January 6, 2011 will be
considered.
DATES:
Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Michael A. Shmilovich, Esq., Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5019; Facsimile: (301) 402–0220; E-mail:
emcdonald on DSK2BSOYB1PROD with NOTICES
ADDRESSES:
VerDate Mar<15>2010
18:39 Dec 06, 2010
Jkt 223001
shmilovm@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published by the United States Patent
and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The
patents and patent applications
intended for licensure disclose or cover
a system, device and method for
rehabilitating dysphagia due to stroke,
ex-tubation or coronary bypass surgery.
Swallowing recovery alleviates the risk
of aspiration by augmenting volitional
control using a simultaneous motor act
(e.g., such as pressing a button to
indicate when they are ready to
swallow). It is believed that such motor
training also initiates sensory
stimulation, immediately preceding the
motor act and that such sensory
stimulation enhances excitation of a
central pattern generator in the brain
stem that augments the volitional
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Status
Expired.
Expired.
Expired.
Expired.
Expired.
Pending.
Pending.
Pending.
Pending.
Pending.
Pending.
Pending.
Pending.
control of swallowing. This principle is
applicable to other neurological
impairments; their associated
enhancement of voluntary motor act
control by the patient initiating
immediately concurrent and related
sensory stimulations. Neurological
impairments that are contemplated
include reflex actions involving
interactions between afferent and
efferent paths (at the spinal cord or in
the brain stem) as well as higher order
interactions. This invention includes
methods for treating neurologically
impaired humans using devices such as
those that produce vibratory
stimulation, pressure stimulation,
auditory stimulation, temperature
stimulation, visual stimulation,
olfactory stimulation, taste stimulation,
or a combination of these. Upon
activation a vibrator moves and vibrates
the larynx. Patients can initiate sensory
stimulation immediately prior to the
patient’s own initiation of a swallow.
E:\FR\FM\07DEN1.SGM
07DEN1
]]>Agencies
[Federal Register Volume 75, Number 234 (Tuesday, December 7, 2010)]
[Notices]
[Pages 76019-76020]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30641]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Complementary & Alternative Medicine; Notice
of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the National Advisory
Council for Complementary and Alternative Medicine (NACCAM) meeting.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
USC, as amended. The grant applications and/or contract Proposals and
the discussions could disclose confidential trade secrets or commercial
property such as patentable materials, and personal information
concerning individuals associated with the grant applications and/or
contract proposals, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council for Complementary
and Alternative Medicine.
Date: February 4, 2011.
Closed: February 4, 2011, 8:30 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 6, Bethesda, MD 20892.
Open: February 4, 2011, 11 a.m. to 4 p.m.
Agenda: Opening remarks by the Director of the National Center
for Complementary and Alternative Medicine, presentation of a new
research initiative, and other business of the Council.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 6, Bethesda, MD 20892.
Contact Person: Martin H. Goldrosen, PhD, Executive Secretary,
Director, Division of Extramural Activities, National Center for
Complementary and Alternative Medicine, National Institutes of
Health, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892. (301)
594-2014.
The public comments session is scheduled from 3:30 to 4 p.m. on
February 4, 2011, but could change depending on the actual time
spent on each agenda item. Each speaker will be permitted 5 minutes
for their presentation. Interested individuals and representatives
of
[[Page 76020]]
organizations are requested to notify Dr. Martin H. Goldrosen,
National Center for Complementary and Alternative Medicine, NIH,
6707 Democracy Boulevard, Suite 401, Bethesda, Maryland 20892, 301-
594-2014, Fax: 301-480-9970. Letters of intent to present comments,
along with a brief description of the organization represented,
should be received no later than 5 p.m. on January 26, 2011. Only
one representative of an organization may present oral comments. Any
person attending the meeting who does not request an opportunity to
speak in advance of the meeting may be considered for oral
presentation, if time permits, and at the discretion of the
Chairperson. In addition, written comments may be submitted to Dr.
Martin H. Goldrosen at the address listed above up to ten calendar
days (February 14, 2011) following the meeting.
Copies of the meeting agenda and the roster of members will be
furnished upon request by contacting Dr. Martin H. Goldrosen,
Executive Secretary, NACCAM, National Center for Complementary and
Alternative Medicine, National Institutes of Health, 6707 Democracy
Boulevard, Suite 401, Bethesda, Maryland 20892, 301-594-2014, Fax
301-480-9970, or via e-mail at naccames@mail.nih.gov.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: nccam.nih.gov/about/naccam, where an agenda and any additional
information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.701, ARRA
Related Biomedical Research and Research Support Awards; 93.213,
Research and Training in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: November 30, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-30641 Filed 12-6-10; 8:45 am]
BILLING CODE 4140-01-P
